Systemic sclerosis & Raynaud's
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A European Scleroderma Trials and Research (EUSTAR) analysis
Authors' conclusion
We found that regression of skin fibrosis is associated with a lower probability of lung progression and better survival at follow up.
Study context
- Population
- EUSTAR patients with diffuse cutaneous systemic sclerosis (dcSSc), baseline modified Rodnan skin score (mRSS) ≥7 and valid mRSS at 12±3 months follow up
- Participants
- 1,257 patients
- Exposure
- Regressive vs stable vs progressive skin fibrosis
- Regressiven = 282
- Stablen = 883
- Progressiven = 92reference
- Outcome
- Progression of lung, renal, cardiac and gastrointestinal manifestations (consensus definitions) and all-cause death
Methodological detailsEUSTAR cohort analysis, multicentre registry, Kaplan-Meier survival analysis, Cox regression, adjusted for baseline mRSS, baseline immunosuppression, baseline FVC and disease duration
- EUSTAR cohort analysis
- Multicentre registry
- Kaplan-Meier survival analysis
- Cox regression
- Adjusted for baseline mRSS, baseline immunosuppression, baseline FVC and disease duration
Main finding
As reported in the abstract
FVC decline ≥10%
- Regressive vs Progressive: P = 0.00003
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| All-cause mortality during follow upRegressive vs Progressive · lower probability; adjusted | P = 0.035 |
Progression of other organ manifestations
- Improvement of skin fibrosis not associated with progression of other organ manifestations
Original publication
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis. Arthritis Res Ther. Published 31 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →